Compounds exhibiting thrombopoietin receptor agonism

Details Compounds exhibiting thrombopoietin receptor agonism Compounds exhibiting thrombopoietin receptor agonism

2004-08-10

2009-10-13

Shiao, Rei-Tsang (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S190000

Reexamination Certificate

active

07601746

ABSTRACT:
A compound represented by the general formula (I):wherein R1is a hydrogen atom, a halogen atom, or the like; R2, R3, and R4are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R5is a hydrogen atom or the like; R6and R7are a hydrogen atom or the like; R8is C1-C3 alkyl or the like; R9is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

REFERENCES:
patent: 5112867 (1992-05-01), Kinoshita et al.
patent: 5413997 (1995-05-01), Kinoshita et al.
patent: 5607952 (1997-03-01), Badorc et al.
patent: 5654322 (1997-08-01), Hirata et al.
patent: 5654622 (1997-08-01), Toya et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 6140330 (2000-10-01), Mori et al.
patent: 6225323 (2001-05-01), Yatscoff et al.
patent: 6306871 (2001-10-01), Yatscoff et al.
patent: 6555519 (2003-04-01), Washburn
patent: 6670387 (2003-12-01), Luengo et al.
patent: 6737382 (2004-05-01), Iwataki et al.
patent: 2003/0195231 (2003-10-01), Takemoto et al.
patent: 2004/0063764 (2004-04-01), Takemoto et al.
patent: 2004/0082626 (2004-04-01), Takemoto et al.
patent: 2005/0153977 (2005-07-01), Sugasawa et al.
patent: 0 295 656 (1992-11-01), None
patent: 0 656 355 (1995-06-01), None
patent: 0 719 775 (1996-07-01), None
patent: 1 207 155 (2002-05-01), None
patent: 1 253 142 (2002-10-01), None
patent: 1253142 (2002-10-01), None
patent: 1 466 912 (2004-10-01), None
patent: 07-112975 (1995-05-01), None
patent: 10-072492 (1998-03-01), None
patent: 10-287634 (1998-10-01), None
patent: 11-001477 (1999-01-01), None
patent: 11-152276 (1999-06-01), None
patent: WO 94/04516 (1994-03-01), None
patent: WO 96/40750 (1996-12-01), None
patent: WO 00/35446 (2000-06-01), None
patent: WO 01/07423 (2001-02-01), None
patent: WO 01/53267 (2001-07-01), None
patent: WO 02/059099 (2002-08-01), None
patent: WO 02/059100 (2002-08-01), None
patent: WO 03/062233 (2003-07-01), None
Vigon et al., “Molecular Cloning and Characterization of MPL, the Human Homolog of the v-mpl Oncogene: Identification of a Member of the Hematopoietic Growth Factor Receptor Superfamily”, Proc. Natl. Acad. Sci. USA, vol. 89, Cell Biology, pp. 5640-5644, (1992).

Affiliated with

Also associated with

Rating

Compounds exhibiting thrombopoietin receptor agonism does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds exhibiting thrombopoietin receptor agonism, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds exhibiting thrombopoietin receptor agonism will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4110312